Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) — Working Capital to Net Assets Ratio
Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a Working Capital to Net Assets ratio of -0.1% as of June 2026. Working capital of $-426.75K (current assets of $217.82K minus current liabilities of $644.57K) is measured against net assets of $495.96 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Drugs Made In America Acquisition II Cor (DMII) liquidity interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Drugs Made In America Acquisition II Corp. Ordinary Shares Working Capital to Net Assets (2024–2025)
This chart shows how Drugs Made In America Acquisition II Corp. Ordinary Shares's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of June 2026, the ratio stands at -0.1%, reflecting working capital of $-426.75K against net assets of $495.96 Million USD. For the complete balance sheet picture, see DMII asset base.
Annual Working Capital to Net Assets for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read DMII current and long-term liabilities for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -0.1% | $-274.83K | $487.16 Million | $26.04K | $300.86K | ▼ -167.3 pp |
| 2024 | 167.2% | $-195.17K | $-116.72K | $59.62K | $254.78K | — |